Clinical Trial Update: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of galantamine hydrobromide for severe Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• GALANTAMINE HYDROBROMIDE (GALANTAMINE HYDROBROMIDE)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Dementia, Alzheimer Disease | Phase 3 | Status: COMPLETED